Nicotine enhances auditory processing in healthy and normal-hearing young adult nonsmokers.

What Was Tested

This randomized controlled trial looks at Therapeutic nicotine (patch, non-peptide).

The researchers postulated that nicotine enhances related auditory processing in humans.

Who Took Part

PubMed indexes the participants as teenagers, young adults and adults, both men and women.

Subjects performed four experiments involving tone-in-noise detection, temporal gap detection, spectral ripple discrimination, and selective auditory attention before and after treatment.

The perceptual differences between posttreatment nicotine and placebo conditions were measured and analyzed as a function of the pre-treatment baseline performance.

How the Study Was Run

The design is described as randomized, single-blind, placebo-controlled and crossover.

Because people in this Therapeutic nicotine (patch, non-peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Only one side, usually the participants, was kept unaware of whether Therapeutic nicotine (patch, non-peptide) was given.

Some participants received a placebo instead of Therapeutic nicotine (patch, non-peptide), giving a reference point.

Each person switched between Therapeutic nicotine (patch, non-peptide) and the comparison at some point, usually with a gap in between.

What Was Measured

Topics PubMed links to this paper include Acoustic Stimulation, Attention, Auditory Perception, Healthy Volunteers, Hearing, Nicotine and Nicotine Chewing Gum.

The authors tagged it with the keywords Acetylcholinergic systems, Auditory processing, Selective attention, Spectral ripple discrimination, Temporal gap detection and Tone in noise detection.

What This Means in Plain Language

The paper is a randomized, single-blind and placebo-controlled study of Therapeutic nicotine (patch, non-peptide).

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2020 (Psychopharmacology), a journal based in Germany.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.